Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) is on the brink of a breakthrough in cancer treatment, with its drug SHR2554 receiving priority review status from China’s Center for Drug Evaluation (CDE). This enhancer of zeste homolog 2 (EZH2) inhibitor is set to revolutionize the treatment of patients with recurrent or refractory peripheral T-cell lymphoma (R/R PTCL), who have previously undergone at least one round of systemic treatment.
SHR2554, an in-house discovery by Hengrui, was granted breakthrough therapy designation (BTD) in China in January 2023, aligning with the commencement of a Phase III study for R/R PTCL. This move underscores Hengrui’s commitment to advancing oncology treatments. In February 2023, Hengrui inked a licensing deal with Treeline Biosciences, granting the US firm exclusive rights to develop, manufacture, and commercialize SHR2554 outside of the Greater China region.
Globally, Epizyme’s Tazverik (tazemetostat), approved in the US in 2020, remains the only commercially available EZH2 inhibitor, treating specific types of sarcoma and lymphoma . However, the field is rapidly evolving with competitors like Pfizer’s PF-06821497, Daiichi Sankyo’s valemetostat, Constellation’s CPI-0209, and Evopoint Bio’s XNW5004 in various stages of development .- Flcube.com
